TY - JOUR
T1 - Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands
T2 - a nationwide prospective observational study (the BRICK study)
AU - Phijffer, Emily W. E. M.
AU - Wildenbeest, Joanne G.
AU - Brouwer, Carole N. M.
AU - de Hoog, Matthijs
AU - Kneyber, Martin C. J.
AU - Maebe, Sofie
AU - Nusmeier, Anneliese
AU - Riedijk, Maaike A.
AU - Woesten-van Asperen, Roelie M.
AU - van Woensel, Job B. M.
AU - Bont, Louis J.
AU - Frederix, Geert J. W.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - Background The implementation of the approved respiratory syncytial virus (RSV) preventive interventions in immunisation programmes is advancing rapidly. Insight into healthcare costs of RSV-related paediatric intensive care unit (PICU) admissions is lacking, but of great importance to evaluate the impact of implementation. Therefore, this study aimed to determine the total annual RSV-related paediatric intensive care healthcare costs in the Netherlands. Methods A nationwide prospective, observational, multicenter study was performed from September 2021 until June 2023. The total annual RSV-related healthcare costs on PICUs in the Netherlands were calculated using RSV-related costs (subgroup I) and consequential costs (subgroup II and III). Subgroup I comprised all PICU admitted infants <= 12 months of age with laboratory-con fi rmed RSV infection. Subgroup II and III consisted of postponed elective PICU admissions and refused acute PICU admissions due to RSV-related lack of PICU capacity. Findings A total of 424 infants with RSV-related PICU admission were included. Median age at PICU admission was 46 days (IQR 25 - 89). The median length of PICU admission was 5 days (IQR 3 - 8). The total RSV-related PICU costs are 3,826,386 in 2021 - 2022, and 3,183,888 in 2022 - 2023. Potential costs averted by RSV preventive interventions is 1.9 to 2.6 million depending on season, and the duration of protection. Interpretation RSV-related PICU admissions cost 3.1 to 3.8 million in the Netherlands during one season. The introduction of new RSV preventive interventions into the Dutch immunisation programme will generate signi fi cant cost-savings on PICUs and decreases the admission burden of PICUs.
AB - Background The implementation of the approved respiratory syncytial virus (RSV) preventive interventions in immunisation programmes is advancing rapidly. Insight into healthcare costs of RSV-related paediatric intensive care unit (PICU) admissions is lacking, but of great importance to evaluate the impact of implementation. Therefore, this study aimed to determine the total annual RSV-related paediatric intensive care healthcare costs in the Netherlands. Methods A nationwide prospective, observational, multicenter study was performed from September 2021 until June 2023. The total annual RSV-related healthcare costs on PICUs in the Netherlands were calculated using RSV-related costs (subgroup I) and consequential costs (subgroup II and III). Subgroup I comprised all PICU admitted infants <= 12 months of age with laboratory-con fi rmed RSV infection. Subgroup II and III consisted of postponed elective PICU admissions and refused acute PICU admissions due to RSV-related lack of PICU capacity. Findings A total of 424 infants with RSV-related PICU admission were included. Median age at PICU admission was 46 days (IQR 25 - 89). The median length of PICU admission was 5 days (IQR 3 - 8). The total RSV-related PICU costs are 3,826,386 in 2021 - 2022, and 3,183,888 in 2022 - 2023. Potential costs averted by RSV preventive interventions is 1.9 to 2.6 million depending on season, and the duration of protection. Interpretation RSV-related PICU admissions cost 3.1 to 3.8 million in the Netherlands during one season. The introduction of new RSV preventive interventions into the Dutch immunisation programme will generate signi fi cant cost-savings on PICUs and decreases the admission burden of PICUs.
KW - Respiratory syncytial viruses
KW - Critical care
KW - Tertiary care centers
KW - Cost of illness
KW - Healthcare costs
KW - INFECTION
U2 - 10.1016/j.lanepe.2024.100965
DO - 10.1016/j.lanepe.2024.100965
M3 - Article
SN - 2666-7762
VL - 43
JO - The Lancet Regional Health – Europe
JF - The Lancet Regional Health – Europe
M1 - 100965
ER -